68Ga-PSMA PET/CT在放射性碘难治性分化型甲状腺癌中的应用及177Lu-PSMA-617首次治疗结果
该研究纳入5例放射性碘难治性分化型甲状腺癌患者,行68Ga-PSMA PET/CT评估177Lu-PSMA-617治疗资格。所有患者PET/CT均显示可疑远处转移摄取,3例符合治疗条件,其中2例接受治疗:1例影像学进展且甲状腺球蛋白从18升至63 μg/L,另1例肺和肝转移暂时部分缓解、甲状腺球蛋白先从17降至9 μg/L但7个月后进展至14 μg/L。作者认为68Ga-PSMA PET/CT可能有助于检出18FDG PET/CT未显示的病灶并筛选治疗对象,但需更多研究。
要点
- 5例放射性碘难治性分化型甲状腺癌患者中,68Ga-PSMA PET/CT均显示可疑远处转移摄取。
- 3例基于摄取符合177Lu-PSMA-617治疗条件,其中2例实际接受治疗。
- 接受治疗的2例中,1例影像学进展且甲状腺球蛋白从18升至63 μg/L,另1例肺和肝转移暂时部分缓解、甲状腺球蛋白先从17降至9 μg/L但7个月后进展至14 μg/L。
核心结论
- 68Ga-PSMA PET/CT在放射性碘难治性分化型甲状腺癌患者中似乎有附加价值,能检出多种类型病灶,其中部分未被18FDG PET/CT显示。
- 68Ga-PSMA PET/CT可能用于识别适合177Lu-PSMA-617治疗的患者;接受治疗的2例中1例显示适度、暂时的缓解。
- 要得出该治疗有效性的结论,需要更多研究。
研究设计与样本
- 研究纳入5例放射性碘难治性分化型甲状腺癌患者,行68Ga-PSMA PET/CT以确定其是否适合177Lu-PSMA-617治疗。
- 68Ga-PSMA PET/CT采用视觉和定量分析;177Lu-PSMA-617治疗反应通过影像学和甲状腺球蛋白值评估。
主要发现
- 所有68Ga-PSMA PET/CT均显示可疑远处转移的示踪剂摄取。
- 基于示踪剂摄取,3例符合177Lu-PSMA-617治疗条件,其中2例接受治疗。
- 1例接受治疗者1个月后影像学显示疾病进展,治疗后数月甲状腺球蛋白值从18 μg/L逐渐升至63 μg/L。
- 另1例接受治疗者肺和肝转移显示部分、暂时缓解,甲状腺球蛋白初始从17 μg/L降至9 μg/L,但治疗7个月后影像学显示疾病进展且甲状腺球蛋白升至14 μg/L。
- 3例患者的68Ga-PSMA PET/CT可与18FDG PET/CT比较:2例在68Ga-PSMA PET/CT上显示额外病灶,1例影像一致。
关键数值与推荐
- 原文未报告诊断阈值、分级标准或推荐条款。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出,要得出该治疗有效性的结论,需要更多研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Differentiated thyroid carcinoma (DTC) is the most common type of thyroid cancer. Treatment with surgery, radioactive iodine (RAI), and TSH suppression is effective in most patients. Five to 15% of patients become RAI refractory and need alternative therapy; however, treatment options are limited. 68Ga-PSMA PET/CT, originally developed for prostate cancer, is also applicable to other malignancies, including thyroid carcinoma. The uptake of PSMA in thyroid carcinoma gives opportunities for imaging and therapy of RAI-refractory DTC. The aim of this study was to analyze imaging on 68Ga-PSMA PET/CT and evaluate the response to 177Lu-PSMA-617 therapy in patients with RAI-refractory DTC. MATERIALS AND METHODS: Five patients with RAI-refractory DTC underwent 68Ga-PSMA PET/CT to determine their eligibility for 177Lu-PSMA-617 therapy. 68Ga-PSMA PET/CTs were analyzed visually and quantitatively. Response to 177Lu-PSMA-617 therapy was evaluated using imaging and thyroglobulin (Tg) values. RESULTS: Tracer uptake suspicious for distant metastases was depicted in all 68Ga-PSMA PET/CTs. Based on tracer uptake, three patients were eligible for 177Lu-PSMA-617 therapy, of whom two were treated. One patient showed disease progression on imaging 1 month later, while her Tg values gradually increased from 18 to 63 μg/L in the months after treatment. Another patient showed partial, temporary response of lung and liver metastases. Her Tg levels initially decreased from 17 to 9 μg/L. However, 7 months after treatment, there was disease progression on imaging and Tg levels had increased to 14 μg/L. Imaging with 68Ga-PSMA PET/CT could be compared to 18FDG PET/CT in three patients. Two patients showed additional lesions on 68Ga-PSMA PET/CT, and one patient showed concordant imaging. CONCLUSION: 68Ga-PSMA PET/CT appears to have added value in patients with RAI-refractory DTC, as it is able to detect various types of lesions, some of which were not picked up by 18FDG PET/CT. Furthermore, 68Ga-PSMA PET/CT might be used to identify patients eligible for treatment with 177Lu-PSMA-617. One of the two patients who underwent 177Lu-PSMA-617 therapy showed a modest, temporary response. To draw conclusions about the effectiveness of this therapy, more research is needed.
引用
- de Vries LH, Lodewijk L, Braat AJAT, et al. 68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617. EJNMMI Res. 2020. PMID: 32144510. doi:10.1186/s13550-020-0610-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。